AYTU has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AYTU has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.
Aytu BioPharma's quarterly accumulated depreciation declined from Mar. 2024 ($-2.87 Mil) to Jun. 2024 ($-2.13 Mil) but then stayed the same from Jun. 2024 ($-2.13 Mil) to Sep. 2024 ($-1.87 Mil).
Aytu BioPharma's annual accumulated depreciation increased from Jun. 2022 ($-2.42 Mil) to Jun. 2023 ($-3.68 Mil) but then stayed the same from Jun. 2023 ($-3.68 Mil) to Jun. 2024 ($-2.13 Mil).
The historical data trend for Aytu BioPharma's Accumulated Depreciation can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aytu BioPharma Annual Data | |||||||||||||||||||||
Trend | Jun15 | Jun16 | Jun17 | Jun18 | Jun19 | Jun20 | Jun21 | Jun22 | Jun23 | Jun24 | |||||||||||
Accumulated Depreciation | Get a 7-Day Free Trial | -0.48 | -1.01 | -2.42 | -3.68 | -2.13 |
Aytu BioPharma Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Accumulated Depreciation | Get a 7-Day Free Trial | -3.99 | -3.08 | -2.87 | -2.13 | -1.87 |
The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.
Thank you for viewing the detailed overview of Aytu BioPharma's Accumulated Depreciation provided by GuruFocus.com. Please click on the following links to see related term pages.
Christopher Brooke | officer: Chief Operating Officer | C/O AYTU BIOPHARMA, INC., 373 INVERNESS PARKWAY, SUITE 206, ENGLEWOOD CO 80112 |
Jarrett Disbrow | officer: Chief Business Officer | 373 INVERNESS PARKWAY, SUITE 200, ENGLEWOOD CO 80112 |
John Jr. Donofrio | director | C/O AYTU BIOSCIENCE, INC., 373 INVERNESS PARKWAY, SUITE 200, ENGLEWOOD CO 80112 |
Carl Dockery | director | P.O. BOX 2477, LAKELAND FL 33806-2477 |
Vivian H Liu | director | |
Mark K Oki | officer: Chief Financial Officer | C/O ALEXZA PHARMACEUTICALS INC, 2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043 |
Joshua R. Disbrow | director, officer: Chief Executive Officer | AMPIO PHARMACEUTICALS, INC., 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111 |
Abhinav Jain | director | C/O AYTU BIOPHARMA, INC., 373 INVERNESS PARKWAY, SUITE 206, ENGLEWOOD CO 80112 |
Wilmot B. Harkey | 10 percent owner | C/O NANTAHALA CAPITAL MANAGEMENT, LLC, 130 MAIN ST. 2ND FLOOR, NEW CANAAN CT 06840 |
Daniel Mack | 10 percent owner | C/O NANTAHALA CAPITAL MANAGEMENT, LLC, 130 MAIN ST. 2ND FLOOR, NEW CANAAN CT 06840 |
Nantahala Capital Management, Llc | 10 percent owner | 130 MAIN ST., 2ND FLOOR, NEW CANAAN CT 06840 |
Greg Pyszczymuka | officer: Chief Commerical Officer | C/O AYTU BIOPHARMA, INC., 373 INVERNESS PARKWAY, SUITE 206, ENGLEWOOD CO 80112 |
Richard I Eisenstadt | officer: Chief Financial Officer | 4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703 |
Gerald W. Mclaughlin | director | 227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428 |
Beth Hecht | director | C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 360, GRAND PRAIRIE TX 75050 |
From GuruFocus
By ACCESSWIRE • 11-07-2024
By ACCESSWIRE • 09-20-2024
By ACCESSWIRE • 05-23-2024
By ACCESSWIRE • 05-09-2024
By ACCESSWIRE • 11-22-2024
By GuruFocus Research • 05-16-2024
By GuruFocus Research • 02-06-2024
By GuruFocus News • 11-14-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.